Clinical Observation of Amlodipine Besylate Combined with Valsartan in the Treatment of Hypertension
10.6039/j.issn.1001-0408.2015.29.32
- VernacularTitle:苯磺酸氨氯地平联合缬沙坦治疗高血压患者的临床观察
- Author:
Qiong JIANG
;
Jun HUANG
;
Kang MAO
;
Shengpeng CHEN
- Publication Type:Journal Article
- Keywords:
Amlodipine besylate;
Valsartan;
Hypertension;
Endothelin-1;
N-terminal B-type natriuretic peptide;
AngiotensinⅡ
- From:
China Pharmacy
2015;(29):4124-4126
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe therapeutic efficacy and safety of amlodipine besylate combined with valsartan in the treatment of hypertension. METHODS:158 patients with hypertension were randomly divided into control group (n=78) and treatment group (n=80). Control group was treated with amlodipine besylate,2.5 mg/time,3 times/d;treatment group was addi-tionally treated with valsartan,80 mg/time,once a day. A treatment course lasted for 4 weeks,and both received 5 courses. Clini-cal efficacy,blood pressure,plasma concentrations of ET-1,NT-proBNP and Ang Ⅱ were compared between 2 groups. RE-SULTS:The compliance rates of treatment group after 4,8,12,16,20 weeks were higher than that of the control group(P<0.05). Compared with control group,SBP and DBP of treatment group were decreased significantly after 4,8,12 and 20 weeks,with sta-tistical significance(P<0.05). After 20 weeks,the serum levels of ET-1,NT-proBNP and Ang Ⅱwere decreased significantly,es-pecially treatment group,with statistical significance (P<0.05). There was no statistical significance in the incidence of ADR be-tween 2 groups (P>0.05). CONCLUSIONS:Amlodipine besylate combined with valsartan can effectively control the blood pres-sure in patients with hypertension,which may be related to the inhibition of ET-1,NT-proBNP and AngⅡ.
